Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.46 |
| ▸ | SYK | P43405 | 4/20 | 0.43 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.43 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.43 |
| ▸ | GSK3B | P49841 | 7/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 7/20 | 0.40 |
| ▸ | WNT1 | P04628 | 3/20 | 0.40 |
| ▸ | TYK2 | P29597 | 4/20 | 0.40 |
| ▸ | HPGDS | O60760 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
| ▸ | MMP13 | P45452 | 1/20 | 0.39 |
| ▸ | MMP14 | P50281 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20092191 | 0.79 | TYK2 (0.48) | IDO1PRMT5WDR77GSK3BDYRK1A | |
| SCHEMBL12492587 | 0.76 | IDO1 (0.58) | IDO1PRMT5WDR77GSK3BDYRK1A | |
| SCHEMBL1431534 | 0.75 | IDO1 (0.55) | IDO1HPGDS | |
| SCHEMBL15507182 | 0.75 | ALDH1A1 (0.58) | IDO1PRMT5WDR77TYK2HPGDS | |
| SCHEMBL30132180 | 0.75 | ALDH1A1 (0.58) | IDO1PRMT5WDR77TYK2HPGDS | |
| SCHEMBL21857535 | 0.74 | KMT2A (0.56) | IDO1PRMT5WDR77GSK3BDYRK1A | |
| SCHEMBL19174931 | 0.74 | IDO1 (0.51) | IDO1PRMT5WDR77GSK3BDYRK1A | |
| SCHEMBL20092319 | 0.74 | IDO1 (0.48) | IDO1PRMT5WDR77GSK3BDYRK1A | |
| SCHEMBL20092109 | 0.72 | SYK (0.48) | SYKTYK2 | |
| SCHEMBL17785817 | 0.72 | PIK3CD (0.47) | PRMT5WDR77 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4206196-A1 | PYRIMIDINE SUBSTITUTED DERIVATIVES AS TYK2 INHIBITORS | Almirall S.A. (ES) | 2023-07-05 | — | — | EP | disclosed |
| US-20210094948-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-04-01 | — | — | US | disclosed |
| US-10647713-B2 | TYK2 inhibitors and uses thereof | NIMBUS LAKSHMI, INC. (US) | 2020-05-12 | — | — | US | disclosed |
| US-20180134700-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-05-17 | — | — | US | disclosed |
| US-20180134700-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-05-17 | — | — | US | disclosed |
| WO-2018075937-A1 | TYK2 INHIBITORS AND USES THEREOF | NIMBUS LAKSHMI, INC. (US) | 2018-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210094948-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | IDO1 429/4885SYK 39/4885PRMT5 690/4885 |
| US-20180134700-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | IDO1 429/4885SYK 39/4885PRMT5 690/4885 |
| US-10647713-B2 | TYK2 inhibitors and uses thereof | TYK2, JAK2, JAK1 | IDO1 429/4885SYK 39/4885PRMT5 690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.